
Cogint (COGT) Stock Forecast & Price Target
Cogint (COGT) Analyst Ratings
Bulls say
Cogent Biosciences Inc. is positioned for significant milestones in 2025, which may enhance its attractiveness as a potential acquisition target, contingent on positive outcomes from the APEX and PEAK trials. The SUMMIT trial results demonstrated substantial benefits, with a notable 87.4% of patients treated with bezuclastinib experiencing a reduction of serum tryptase, indicating its therapeutic effectiveness. Furthermore, the adjustments to the discounted cash flow (DCF) valuation reflect confidence in a 90% probability of approval for bezuclastinib in treating gastrointestinal stromal tumors, alongside a raised peak penetration rate, showcasing the stock's positive outlook in the biotechnology sector.
Bears say
Cogent Biosciences faces several significant risks that contribute to a negative financial outlook, including potential negative clinical data for its drug bezuclastinib and slower-than-expected development timelines. The company has recorded growing net losses, including a net loss of $80.9 million in the third quarter of 2025, which exceeded prior estimates. Additionally, the projected full-year 2025 net loss per share is anticipated to be $2.39, highlighting ongoing financial challenges and concerns regarding the company's commercial success and potential dilution of shareholder value.
This aggregate rating is based on analysts' research of Cogint and is not a guaranteed prediction by Public.com or investment advice.
Cogint (COGT) Analyst Forecast & Price Prediction
Start investing in Cogint (COGT)
Order type
Buy in
Order amount
Est. shares
0 shares